Virtual variety is guaranteed

In talking to virtual biotech experts, one learns quickly that almost everyone in this game takes slightly or drastically different approaches to building their companies. Some favor certain tech tools, while others innovate with their business models. Nimbus, for example, has a corporate structure that supports the formation of multiple LLCs to tackle specific targets and offers multiple exit opportunities to investors. AstraZeneca's ($AZN) iMed has taken some of the tech insights that went into Chorus and then added in some other components based on the needs of a neuroscience R&D venture.

Please feel free to chime in with any additional insights that could help biotech pros with their own virtual business ambitions.

Virtual variety is guaranteed

Suggested Articles

Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.

In this week's EuroBiotech Report, Healx raises $56 million, Boehringer's VC wing backs anti-cancer virus startup and Ipsen bags Blueprint drug.

In our EuroBiotech roundup this week, GammaDelta forms antibody spinout, gene therapy startup raises cash and Amsterdam plans medical business park.